



*Developing new therapies through the manipulation of
the tissue stroma*

Stromal cells instruct the tissue microenvironment

*Emerging research: Stromal cells modify disease
via the production of tissue cytokines*



Target 1:

↑ in Inflammation


Target 2:

↑ in Cancer


Target molecules – Mechanism of action

Bone morphogenic proteins (BMP2/4) are secreted by stromal cells to modulate tissue homeostasis.


Gremlins regulate BMP activity preventing signaling via the BMP receptor.




Product and development pipeline




STx_001 patent family



Represented by Dr. Philipp Marchand, Vossius & Partner, Basel  VOSSIUS

Licensing:
Agreement with Kantonsspital St. Gallen for the exclusive worldwide license


Unmet medical need: Myocarditis and inflammatory cardiomyopathy




*44 y.o. female patient, 3 weeks after onset of flu-like symptoms
(Courtesy: M. Kurrer, University Hospital Zurich)*

- Myocarditis: inflammation of the heart muscle, leading to loss of cardiomyocytes
- Frequent cause of sudden death in young adults
- **Current treatment recommendations: reduced physical activity / pericardial involvement:
ibuprofen and colchicine / heart failure treatment**

STx_001: Drug development pipeline




Therapeutic efficacy of STx_001 in a preclinical model of myocarditis



Treatment with STx_001 secured survival, prevented dilated cardiomyopathy and cardiac fibrosis

Unmet medical need for treatment of cardiac inflammation



Immunotherapeutics targeting cardiac diseases, which contribute to a substantial global health burden, are under-represented.

Patient trajectories as basis for proof-of-concept trial

Patients to treat
in PoC trial →

Myocarditis
ICD-I40, I41, I51.4



740,800 p.p.a

EU+US

112'242 p.p.a

Chronic myocarditis



890,000 – 2,200,000 p.p.a

EU+US

259'700 – 649'300 p.p.a

Cardiomyopathy
ICD-I42

Heart Failure
ICD-I50

Sources: Global Health Metrics 2019

Company development

Target
Discovery



STx_001
Humanized



Investigative
New Drug



Q1
2019

Seed Financing:
1 Mio CHF
- BaseLaunch
- USZ Innovation
- Startfeld Foundation

Q1
2023

Series A:
15+ Mio CHF for
- IND application
- FIH trial

2025

Summary of planned activities		Timeline		Cost (MCHF)
		2023	2024	
GMP production (Lonza)	a. Pilot drug assessment	◆		3.1
	b. cGMP drug		◆	3.0
GLP toxicology (Charles river)	c. Toxicological evaluation		◆	1.8
FIH trial	d. Preparation phase		◆	0.5
	e. FIH trial		◆	4 - 6

Company Development – Stromal Therapeutics

Board



Prof. Dr. Burkhard Ludewig

Co-Founder
Stromal cell biology pioneer

*Head of Medical Research Center, Kantonsspital St. Gallen
Head of Translational Cardiology, University Hospital Zurich*



Dr. Lucas Onder

Co-Founder
Stromal cells in disease expert

*Senior Scientist at Medical Research Center,
Kantonsspital St. Gallen*



Prof. Leslie Cooper, JR., M.D.

Expert in myocarditis and clinical development

*Chair of Cardiovascular Medicine,
Mayo Clinic, Florida, USA*

Company Employees



Dr. Hung-Wei Cheng

Co-Founder
Head R&D, Molecular biology expert

*Senior Scientist at Medical Research Center,
Kantonsspital St. Gallen*



Céline Engetschwiler

Chief Operating Officer

*Lab manager at Medical Research Center,
Kantonsspital St. Gallen*

Currently recruiting:

Biopharmaceutical executive